This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TNFSF12 / Tumor necrosis factor ligand superfamily member 12 · IHC design guide
Design Immunohistochemistry for TNFSF12
Plan TNFSF12 IHC in paraffin sections using the catalog antibody’s fixation, dilution and chromogenic detection evidence (datasheet A02009-2). Compare cytoplasmic tissue staining with suitable controls while accounting for the secreted form and uncertain tissue evidence (HPA tissue IHC; UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
TNFSF12 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining (HPA tissue IHC); membrane and secreted forms (UniProt) | |
| Staining pattern | Cytoplasmic staining in most tissues; plasma positive (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A02009-2) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Bone marrow+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Formaldehyde-fixed paraffin sections (selected-SKU IHC image A02009-2); keep fixation consistent. (standard IHC practice; not target-specific) | |
| Caveat | Secreted variants can complicate tissue localisation (HPA tissue IHC) | |
| Regulation | Expression regulation not specified (UniProt) | |
| Isoform / epitope | 2 isoforms; cleavage and epitope location matter (UniProt) |
Section 1
Recommended TNFSF12 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by one published TNFSF12 staining workflow (PMC13371701).
| Sample | Formaldehyde-fixed, paraffin-embedded human brain tissue (datasheet A02009-2) |
| Fixation | Image formalin-fixed; duration unreported (datasheet A02009-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6 (datasheet A02009-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% serum (datasheet A02009-2) |
| Primary antibody | Rabbit anti-TNFSF12, 5-10 μg/mL (datasheet A02009-2) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | TNFSF12-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues. Positivity in plasma. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6 heat retrieval (datasheet: citrate pH 6 HIER; PMC13371701: microwave citrate pH 6.0).
Section 2
What Is the Expected TNFSF12 Staining Pattern?
TNFSF12 is a membrane protein with an extracellular region and a secreted form (UniProt O43508 topology and processing). In tissue IHC, expect predominantly cytoplasmic staining in glandular cells and muscle cells, with possible plasma positivity (HPA: tissue profile). Treat the pattern as provisional: HPA rates tissue IHC reliability Uncertain because the antibody targets proteins from more than one gene, and the secreted variant complicates location comparisons (HPA: reliability description).
| Cytoplasmic signal in heart cardiomyocytes, skeletal myocytes, or duodenal or small-intestinal glandular cells. | These are reported High-staining cells and fit the broad cytoplasmic tissue profile (HPA: tissue IHC). Compare intensity within the same run; a plausible pattern alone cannot establish TNFSF12 specificity because tissue IHC reliability is Uncertain (HPA: reliability description). |
| Predominantly nuclear staining with little cytoplasmic signal in an expected positive tissue. | A nuclear-only pattern conflicts with the reported cytoplasmic profile and membrane/secreted annotation (HPA: tissue profile; UniProt O43508 subcellular location). Consider nonspecific staining or an imaging or scoring artefact (general IHC practice). |
| Strong staining in cells reported as Not detected, such as lung alveolar cells or liver cholangiocytes. | This differs from the cited cell-level observations (HPA: lung and liver tissue IHC). Check cell identity, cross-reactivity and endogenous detection activity (general IHC practice). Given HPA's Uncertain reliability, the mismatch raises a question; it does not prove a false positive (HPA: reliability description). |
| Diffuse colour across cells and surrounding tissue, obscuring cell boundaries. | This cannot be scored confidently against HPA's cell-level pattern (HPA: tissue profile). Uneven blocking, excess detection reagent or inadequate washing can produce background (general IHC practice); a widespread signal should not be counted as TNFSF12-positive cells. |
| No signal in heart cardiomyocytes or skeletal myocytes. | Both cell types are reported High by tissue IHC, so an absent signal warrants a run-level check (HPA: heart and skeletal muscle). Confirm tissue preservation, retrieval, antibody and detection steps with appropriate controls (general IHC practice), while retaining HPA's Uncertain specificity caveat. |
💡Expected TNFSF12 appearanceA convincing positive is discernible cytoplasmic staining in reported High cells, such as heart cardiomyocytes or small-intestinal glandular cells, with separable cell outlines; uniform haze or isolated nuclear colour is suspect (HPA: tissue profile; general IHC practice).
| Membrane form and shedding | Residues 22–42 span the membrane; residues 43–249 are extracellular, and residues 94–249 form a secreted chain (UniProt O43508 topology and processing). Membrane association or extracellular material is biologically plausible, but the tissue IHC reference pattern remains mainly cytoplasmic (HPA: tissue profile). |
| Antibody epitope | The supplied record gives no epitope for the tissue IHC antibody. Whether it recognizes membrane and secreted forms cannot be resolved from their listed boundaries alone (UniProt O43508 processing); interpret a compartment difference cautiously. |
| Isoforms and glycosylation | UniProt lists two isoforms, including TWE-PRIL, and a glycosylation site at residue 139 (UniProt O43508 isoforms and glycosylation). The payload does not establish which forms the tissue antibody detects or any glycosylation effect on IHC staining. |
| Tissue selection | Use reported High cells to assess visibility; skin keratinocytes are Low, while bone-marrow hematopoietic cells are Not detected (HPA: tissue IHC). These categories describe observations, not absolute positive or negative controls, given the Uncertain reliability (HPA: reliability description). |
| Antibody validation | HPA052967 has Uncertain IHC validation; the overall tissue profile is also Uncertain and awaits external verification (HPA: antibody validation and reliability description). Reproduction with an independent, suitable antibody would strengthen an interpretation (general IHC practice). |
| IF/ICC Q: Should vesicle staining guide this IHC result? | A: HPA reports approved vesicle localization by ICC-IF, but cautions that its antibodies target proteins from multiple genes (HPA: subcellular summary). Use that observation as context, not as a required chromogenic tissue IHC pattern; evaluate IF/ICC on its own guide page. |
| Situation | Likely cause | Next action |
|---|---|---|
| A reported High tissue has no visible staining. | A failed staining or detection step is possible (general IHC practice); HPA's High designation does not guarantee every section will stain (HPA: tissue IHC; reliability description). | Check section quality and run controls, then review retrieval, antibody incubation and chromogen development records (general IHC practice). Do not assign a TNFSF12-specific retrieval requirement from these sources. |
| Colour spreads through nearly every cell and extracellular space. | Background from detection chemistry or insufficient washing may mask the reported cell-level pattern (general IHC practice; HPA: tissue profile). | Inspect a no-primary control, wash steps and detection conditions; score only distinguishable cellular signal (general IHC practice). |
| Blood-rich regions or plasma appear positive. | Plasma positivity is part of the reported tissue profile (HPA: tissue IHC); it can complicate assignment of colour to nearby cells (general IHC practice). | Compare the cellular compartment and section morphology before assigning positivity to a specific cell type (general IHC practice). |
| Strong colour appears in HPA Not detected cells. | Cell misidentification, cross-reactivity or endogenous detection activity is possible (general IHC practice); HPA reports no staining in those specified cells (HPA: tissue IHC). | Recheck cell identity and no-primary controls, then compare an independent antibody if available (general IHC practice); retain the HPA Uncertain caveat. |
| Staining is nuclear rather than cytoplasmic. | Nuclear staining does not match the HPA cytoplasmic profile or UniProt membrane/secreted location (HPA: tissue profile; UniProt O43508 subcellular location). | Check counterstain interpretation and controls, then review antibody and detection specificity (general IHC practice). |
| Tissue staining and reported expression seem inconsistent. | UniProt lists adult lung and spleen expression, whereas HPA reports Not detected in lung alveolar cells and spleen red-pulp cells (UniProt O43508 tissue specificity; HPA: tissue IHC). HPA warns that secreted variants complicate RNA–protein location comparisons. | Compare the named cell population and assay type, and report the discrepancy without converting tissue-wide expression into a predicted cell-level IHC result (HPA: reliability description; general IHC practice). |
Experiment evidence
IHC & IF images showing TNFSF12 staining
A02009-2 · IHCImmunohistochemistry Validation of TWEAK in Human Brain Tissue Immunohistochemical analysis of paraffin-embedded human brain tissue using an
A02009-2 · IHCImmunohistochemistry Validation of TWEAK in Mouse Brain Tissue Immunohistochemical analysis of paraffin-embedded mouse brain tissue using an
A02009-2 · IFImmunofluorescence Validation of TWEAK in Mouse Brain Tissue Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse brain tissue labe
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000239697-TNFSF12/tissue/cerebral+cortex#imid_1635872
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000239697-TNFSF12/tissue/colon#imid_1635790
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000239697-TNFSF12/tissue/liver#imid_1635807
HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000239697-TNFSF12/tissue/pancreas#imid_1635750
HPA · ICC-IF SH-SY5YHuman Protein Atlas immunofluorescence, SH-SY5Y, antibody HPA035984; green = TNFSF12, blue = nucleus, red = microtubules.
HPA · ICC-IF SH-SY5YHuman Protein Atlas immunofluorescence, SH-SY5Y, antibody HPA035984; green = TNFSF12, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for TNFSF12 IHC & IF
🧪Run heart muscle first: cardiomyocytes should stain (HPA: High in cardiomyocytes). Use bone marrow hematopoietic cells as the negative tissue (HPA: Not detected); on the heart slide, assess neighboring noncardiomyocyte cells for background without assuming they are TNFSF12-negative (HPA: High is assigned to cardiomyocytes).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Bone marrow (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show TNFSF12 in SH-SY5Y, SK-MEL-30, U2OS, with annotated localisation: Vesicles (approved) (HPA subcellular).
Technical controls: Include no-primary (secondary-only), host- and immunoglobulin class-matched isotype controls appropriate to the primary antibody’s clonality, and matched TNFSF12-knockout material as a biological negative. Quench endogenous peroxidase in heart sections before HRP detection (selected-SKU caption: HRP secondary).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported; the selected-SKU caption describes formaldehyde fixation but gives no duration (selected-SKU caption: formaldehyde fixation). Heat retrieval in citrate buffer at pH 6 is a documented IHC condition, but retrieval dependency is unreported (selected-SKU caption: heat retrieval with citrate buffer, pH 6). The evidence does not establish whether frozen sections or IF are easier; assess cardiac pigment and autofluorescence when interpreting punctate signal, particularly in IF (HPA: vesicular ICC-IF localization carries a multiple-gene antibody caution).
HPA tissue IHC evidence for TNFSF12
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Caution, targets protein from more than one gene. At least one protein variant secreted, tissue location of RNA and protein might differ and correlation is complex. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | High | Protein (IHC) | HPA → |
| Rectum | Glandular cells | High | Protein (IHC) | HPA → |
| Skeletal muscle | Myocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Liver | Cholangiocytes | Not detected | Protein (IHC) | HPA → |
| Lung | Alveolar cells | Not detected | Protein (IHC) | HPA → |
| Nasopharynx | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Salivary gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced TNFSF12 IHC Tips
Troubleshoot TNFSF12 staining in paraffin sections by checking retrieval, compartment, controls and scoring before interpreting tissue differences.
What should I change when TNFSF12 staining is weak after retrieval?
Start with heat-mediated retrieval in citrate buffer at pH 6 (datasheet A02009-2). The catalog antibody stained paraffin-embedded human brain at 10 µg/ml after this retrieval, with overnight primary incubation at 4°C (datasheet A02009-2). Check that sections remain attached and compare a fresh retrieval run with a matched section processed without retrieval; excessive heating can damage morphology (standard IHC practice). If staining remains weak, test a different retrieval buffer or heating duration on adjacent sections while holding antibody concentration and detection constant (standard IHC practice). Score signal against the no-primary control, because stronger color alone does not establish specificity (standard IHC practice).
Could fixation explain weak or uneven TNFSF12 staining?
Target-specific fixation sensitivity is unknown from the supplied evidence; establish it experimentally rather than assuming an optimal fixation duration. Record fixative, time to fixation, tissue thickness and fixation duration for each specimen, then compare sections processed together with the same retrieval and detection conditions (standard IHC practice). Uneven staining near section edges or across thicker tissue can reflect processing differences, so review morphology and compare adjacent sections before changing antibody concentration (standard IHC practice). The catalog example used formaldehyde-fixed, paraffin-embedded human brain, citrate retrieval at pH 6 and 10 µg/ml antibody; that example does not define fixation sensitivity across specimens (datasheet A02009-2).
Should TNFSF12 staining be membranous, cytoplasmic or extracellular?
TNFSF12 has a membrane form with a transmembrane segment at residues 22–42 and an extracellular region at 43–249 (UniProt O43508 topology). A processed form spanning residues 94–249 is secreted, so extracellular staining can be plausible but needs careful control comparison (UniProt O43508 processing). HPA describes predominantly cytoplasmic tissue staining and plasma positivity, while its tissue IHC reliability is uncertain because the antibody targets proteins from more than one gene (HPA tissue IHC). For each compartment, compare staining with no-primary controls and tissue morphology, and avoid treating diffuse deposits or section-edge staining as localisation evidence (standard IHC practice).
How does epitope position affect interpretation of TNFSF12 IHC?
Ask the antibody supplier for the immunogen or mapped epitope before assigning a stained compartment to a particular TNFSF12 form (standard IHC practice). Residues 1–21 are cytoplasmic, 22–42 span the membrane, and 43–249 are extracellular in the membrane form (UniProt O43508 topology). The secreted chain begins at residue 94, while the record also lists a TWE-PRIL isoform; an unmapped antibody cannot distinguish those forms by staining pattern alone (UniProt O43508 processing and isoforms). Compare validated antibodies against distinct mapped regions, if available, on serial sections with matched controls before claiming form-specific expression (standard IHC practice).
How should I investigate TNFSF12 localisation by multiplex IF?
Use IF as a separate optimisation: the catalog example establishes chromogenic paraffin-section IHC conditions, not an IF dilution or fixation condition (datasheet A02009-2). Pair TNFSF12 with a validated marker for the cell population under study and include single-stain controls to assess channel bleed-through (standard IF practice). Measure unstained tissue autofluorescence first, then choose spectrally separated fluorophores and exposure settings that keep the TNFSF12 channel distinguishable (standard IF practice). For an antibody recognising the cytoplasmic residues 1–21, test gentle permeabilisation; for an extracellular epitope within 43–249, compare permeabilised and non-permeabilised preparations (UniProt O43508 topology; standard IF practice).
What causes diffuse brown signal in TNFSF12 sections?
First compare the stained section with a no-primary control and inspect whether brown deposits follow tissue boundaries, damaged areas or endogenous pigment (standard IHC practice). Include a peroxidase block before HRP detection and assess background after the chromogen step, because endogenous enzyme activity can imitate antibody signal (standard IHC practice). The catalog brain example used 10% serum for 1 hour at room temperature and an HRP secondary at 1:250; these are starting conditions, not proof that every tissue will be clean (datasheet A02009-2). If background persists, titrate primary antibody around the documented 10 µg/ml condition while keeping retrieval and development matched (datasheet A02009-2; standard IHC practice).
How should I score TNFSF12 staining across sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the compartment and cell population before scoring, because TNFSF12 has membrane and secreted forms and HPA reports cytoplasmic tissue staining with uncertain reliability (UniProt O43508 processing; HPA tissue IHC). For cellular staining, report the percentage of positive cells and an H-score from intensity categories 0–3; use the same thresholds across the comparison set (standard IHC practice). For a defined region, positive-cell density per mm² can supplement those scores when cell abundance varies (standard IHC practice). Normalise to evaluable cells or tissue area, document excluded necrotic or folded regions, and review no-primary controls before setting the positivity threshold (standard IHC practice).
When is TNFSF12 staining convincing rather than artefactual?
Interpret a signal as stronger evidence when it repeats in comparable sections, exceeds no-primary background and fits intact cellular or extracellular anatomy (standard IHC practice). Membrane-associated and extracellular patterns are biologically plausible for the membrane and secreted TNFSF12 forms, while a nuclear-only pattern warrants scrutiny (UniProt O43508 topology and processing). HPA reports high staining in heart cardiomyocytes and skeletal muscle myocytes, but rates its tissue IHC reliability uncertain because the antibody targets more than one gene (HPA tissue IHC). Reject isolated section-edge, necrotic or endogenous peroxidase-associated color as proof of expression, and confirm disputed patterns with an independent validated reagent (standard IHC practice).
Boster reagents
Best TNFSF12 / Tumor necrosis factor ligand superfamily member 12 IHC Antibodies
A02009-2 has IHC images from human and mouse paraffin-embedded brain tissue (IHC image captions) and an IF image from mouse brain tissue (IF image caption).
Real IHC data
Anti-TWEAK TNFSF12 Antibody
Cat # A02009-2
A02009-2 was demonstrated by IHC on human paraffin-embedded brain tissue at 10 μg/mL with formaldehyde fixation (human IHC image caption). The same SKU was demonstrated by IHC on mouse paraffin-embedded brain tissue at 5 μg/mL (mouse IHC image caption) and by IF on 4% paraformaldehyde-fixed mouse brain tissue (IF image caption).
Which to pick: Choose A02009-2 for tissue IHC: its application list includes IHC-P (catalog), and its images cover formaldehyde-fixed, paraffin-embedded human and mouse brain sections (IHC image captions). For IF, A02009-2 has a mouse brain image at 20 μg/mL (IF image caption); ICC validation is unreported (catalog). It is also the cross-species IHC choice here, with Human and Mouse reactivity (catalog) and IHC images for both species (IHC image captions); its host is rabbit, while clonality is unreported (catalog).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O43508 (TNF12_HUMAN, Tumor necrosis factor ligand superfamily member 12).
- Human Protein Atlas. TNFSF12 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. TNFSF12 subcellular location (ICC-IF): Localized to vesicles. Caution: Based on antibodies targeting proteins from multiple genes..
- Human Protein Atlas. TNFSF12 antibody validation summary (2 antibodies).
- A Transcriptomic Analysis of Cancer-Stromal Interactome in Lung Cancer Xenograft Models. Cancer science 2026 — PMC12951093.
- Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer Patients. Journal of oncology 2022 — PMC9045999.
- APOE+ macrophages induce tumor cell metastatic characteristics via TNFSF12/TNFRSF12A signaling, correlating with poor patient prognosis. Cancer cell international 2026 — PMC13371701.
- Endothelial AGGF1 promotes retinal angiogenesis by coordinating TNFSF12/FN14 signalling. Nature communications 2025 — PMC11794540.
- PubMed PMID:9405449 — UniProt-cited evidence.
- PubMed PMID:9560343 — UniProt-cited evidence.
- PubMed PMID:12411489 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for TNFSF12 (Tumor necrosis factor ligand superfamily member 12). Expected localisation Cytoplasmic staining (HPA tissue IHC); membrane and secreted forms (UniProt). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A02009-2). Validated IHC antibody: A02009-2 at 5-10 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Bone marrow. IHC-P workflow on paraffin sections. Protocol steps: 1. Sample: Formaldehyde-fixed, paraffin-embedded human brain tissue (datasheet A02009-2); 2. Fixation: Image formalin-fixed; duration unreported (datasheet A02009-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 (datasheet A02009-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% serum (datasheet A02009-2); 8. Primary antibody: Rabbit anti-TNFSF12, 5-10 μg/mL (datasheet A02009-2); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Formaldehyde-fixed paraffin sections (selected-SKU IHC image A02009-2); keep fixation consistent. (standard IHC practice; not target-specific); Caveat: Secreted variants can complicate tissue localisation (HPA tissue IHC); Isoform / epitope: 2 isoforms; cleavage and epitope location matter (UniProt); Regulation: Expression regulation not specified (UniProt). Evidence: UniProt O43508, HPA tissue IHC · Uncertain, HPA ICC-IF · vesicles. Caution: Based on antibodies targeting proteins from…, Datasheet A02009-2, PMC13371701. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/TNFSF12/immunohistochemistry-ihc-guide.